Abstract
The recent comprehensive review by Trost et al. highlighting the impact of androgen deprivation therapy (ADT) with luteinising hormone‐releasing hormone agonists (LHRHa) on quality of life (QoL) of prostate cancer survivors is timely in view of increasing usage and accumulating evidence of its harms [1]. LHRHa were developed because oral estrogen, a major option for treating prostate cancer through ADT in the second half of the 20th century, was discontinued due to its excessive cardiovascular (CVS) mortality [2].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
